Global Life Sciences company: integration across two continents

The case records a EUR120M programme across two continents for an anonymised Global Life Sciences company, delivered under cost. It does not quantify the amount below cost. The figures describe programme scale and the reported result; they should not be converted into a claim about transaction value or synergies.

Yes. The integration scope considers the intended destination alongside the acquired estate and the value case. The work establishes what should be retained, migrated, integrated or replaced and the dependencies behind those choices. The appropriate route follows that assessment rather than an assumption that every target needs the same change.

The programme identifies the technology work required before the relevant benefit can be realised. That may include preparation, migration and operational acceptance, depending on scope. Heremba provides technology delivery and evidence; the client retains responsibility for financial benefit recognition and the operating decisions behind the wider synergy plan.

A new integration engagement can include a repeatable playbook for later acquisitions. It records reusable decisions, scope questions and dependencies while allowing for differences between targets. This is a feature of the related service, not an additional claim about the specific life sciences programme described here.